Lawrence F. Bronk

Lawrence F. Bronk

Auto-generated profile, based on publicly available information

Lawrence F. Bronk

The University of Texas M. D. Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2010 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
GSGlauco R. Souza
Glauco R. Souza
JMJennifer R. Molina
Jennifer R. Molina
RRRobert M. Raphael
Robert M. Raphael
MOMichael G. Ozawa
Michael G. Ozawa
DSDaniel J. Stark
Daniel J. Stark
RPRenata Pasqualini
Renata Pasqualini

18 May 2015 in Scientific Reports
Verified
Journal Article
Open access
FGFada Guan
Fada Guan
LBLawrence Bronk
Lawrence Bronk
UTUwe Titt
Uwe Titt
SLSteven H. Lin
Steven H. Lin
DMDragan Mirkovic
Dragan Mirkovic
DGDavid Grosshans
David Grosshans
The physical properties of particles used in radiation therapy, such as protons, have been well characterized and their dose distributions are superior to photon-based treatments. However, proton therapy may also have inherent biologic advantages that have not been capitalized on. Unlike photon beams, the linear energy transfer (LET) and hence biologic effectiveness of particle beams varies along the beam path. Selective placement of areas of high effectiveness could enhance tumor cell kill and simultaneously spare normal tissues. However, previous methods for mapping spatial variations in biologic effectiveness are time-consuming and often yield inconsistent results with large uncertainties. Thus the data needed to accurately model relative biological effectiveness to guide novel treatment planning approaches are limited. We used Monte Carlo modeling and high-content automated clonogenic survival assays to spatially map the biologic effectiveness of scanned proton beams with high accuracy and throughput while minimizing biological uncertainties. We found that the relationship between cell kill, dose and LET, is complex and non-unique. Measured biologic effects were substantially greater than in most previous reports, and non-linear surviving fraction response was observed even for the highest LET values. Extension of this approach could generate data needed to optimize proton therapy plans incorporating variable RBE.

9 May 2011 in Applied Physics Letters
Verified
Journal Article
Open access
PDF file
JPJerimy C. Polf
Jerimy C. Polf
LBLawrence F. Bronk
Lawrence F. Bronk
WDWouter H. P. Driessen
Wouter H. P. Driessen
WAWadih Arap
Wadih Arap
RPRenata Pasqualini
Renata Pasqualini
MGMichael Gillin
Michael Gillin
The development and use of sensitizing agents to improve the effectiveness of radiotherapy have long been sought to improve our ability to treat cancer. In this letter, we have studied the relative biological effectiveness of proton beam radiotherapy on prostate tumor cells with and without internalized gold nanoparticles. The effectiveness of proton radiotherapy for the killing of prostate tumor cells was increased by approximately 15%–20% for those cells containing internalized gold nanoparticles.

8 October 2015 in Medical Physics
Verified
Journal Article
Open access
PDF file
FGFada Guan
Fada Guan
CPChristopher Peeler
Christopher Peeler
LBLawrence Bronk
Lawrence Bronk
CGChangran Geng
Changran Geng
RTReza Taleei
Reza Taleei
UTUwe Titt
Uwe Titt
Purpose: The motivation of this study was to find and eliminate the cause of errors in dose‐averaged linear energy transfer (LET) calculations from therapeutic protons in small targets, such as biological cell layers, calculated using the geant 4 Monte Carlo code. Furthermore, the purpose was also to provide a recommendation to select an appropriate LET quantity from geant 4 simulations to correlate with biological effectiveness of therapeutic protons.Methods: The authors developed a particle tracking step based strategy to calculate the average LET quantities (track‐averaged LET, LETt and dose‐averaged LET, LETd) using geant 4 for different tracking step size limits. A step size limit refers to the maximally allowable tracking step length. The authors investigated how the tracking step size limit influenced the calculated LETt and LETd of protons with six different step limits ranging from 1 to 500 μm in a water phantom irradiated by a 79.7‐MeV clinical proton beam. In addition, the authors analyzed the detailed stochastic energy deposition information including fluence spectra and dose spectra of the energy‐deposition‐per‐step of protons. As a reference, the authors also calculated the averaged LET and analyzed the LET spectra combining the Monte Carlo method and the deterministic method. Relative biological effectiveness (RBE) calculations were performed to illustrate the impact of different LET calculation methods on the RBE‐weighted dose.Results: Simulation results showed that the step limit effect was small for LETt but significant for LETd. This resulted from differences in the energy‐deposition‐per‐step between the fluence spectra and dose spectra at different depths in the phantom. Using the Monte Carlo particle tracking method in geant 4 can result in incorrect LETd calculation results in the dose plateau region for small step limits. The erroneous LETd results can be attributed to the algorithm to determine fluctuations in energy deposition along the tracking step in geant 4. The incorrect LETd values lead to substantial differences in the calculated RBE.Conclusions: When the geant 4 particle tracking method is used to calculate the average LET values within targets with a small step limit, such as smaller than 500 μm, the authors recommend the use of LETt in the dose plateau region and LETd around the Bragg peak. For a large step limit, i.e., 500 μm, LETd is recommended along the whole Bragg curve. The transition point depends on beam parameters and can be found by determining the location where the gradient of the ratio of LETd and LETt becomes positive.

26 February 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MCMarina Cardó-Vila
Marina Cardó-Vila
RGRicardo J. Giordano
Ricardo J. Giordano
RSRichard L. Sidman
Richard L. Sidman
LBLawrence F. Bronk
Lawrence F. Bronk
ZFZhen Fan
Zhen Fan
RPRenata Pasqualini
Renata Pasqualini
The epidermal growth factor receptor (EGFR), a tyrosine kinase, is central to human tumorigenesis. Typically, three classes of drugs inhibit tyrosine kinase pathways: blocking antibodies, small kinase inhibitors, and soluble ligand receptor traps/decoys. Only the first two types of EGFR-binding inhibitory drugs are clinically available; notably, no EGFR decoy has yet been developed. Here we identify small molecules mimicking EGFR and that functionally behave as soluble decoys for EGF and TGFα, ligands that would otherwise activate downstream signaling. After combinatorial library selection on EGFR ligands, a panel of binding peptides was narrowed by structure–function analysis. The most active motif was CVRAC (EGFR 283–287), which is necessary and sufficient for specific EGFR ligand binding. Finally, a synthetic retro-inverted derivative, D (CARVC), became our preclinical prototype of choice. This study reveals an EGFR-decoy drug candidate with translational potential.

5 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
LBLawrence Bronk
Lawrence Bronk
FGFada Guan
Fada Guan
DPDarshana Patel
Darshana Patel
DMDuo Ma
Duo Ma
BKBenjamin Kroger
Benjamin Kroger
DGDavid Grosshans
David Grosshans
Large amounts of high quality biophysical data are needed to improve current biological effects models but such data are lacking and difficult to obtain. The present study aimed to more efficiently measure the spatial distribution of relative biological effectiveness (RBE) of charged particle beams using a novel high-accuracy and high-throughput experimental platform. Clonogenic survival was selected as the biological endpoint for two lung cancer cell lines, H460 and H1437, irradiated with protons, carbon, and helium ions. Ion-specific multi-step microplate holders were fabricated such that each column of a 96-well microplate is spatially situated at a different location along a particle beam path. Dose, dose-averaged linear energy transfer (LETd), and dose-mean lineal energy (yd) were calculated using an experimentally validated Geant4-based Monte Carlo system. Cells were irradiated at the Heidelberg Ion Beam Therapy Center (HIT). The experimental results showed that the clonogenic survival curves of all tested ions were yd-dependent. Both helium and carbon ions achieved maximum RBEs within specific yd ranges before biological efficacy declined, indicating an overkill effect. For protons, no overkill was observed, but RBE increased distal to the Bragg peak. Measured RBE profiles strongly depend on the physical characteristics such as yd and are ion specific.